ArticleCancers2026
Prescription Monitoring Program Review Among Patients with Cancer Receiving Opioids at a Safety-Net Palliative Medicine Clinic.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionPrescription monitoring programs (PMPs) are commonly used to monitor non-medical opioid use (NMOU); however, the effectiveness of PMPs for identifying cancer patients with risk factors is not well known.
methodsThis study assessed the frequency and predictors of concerning PMP findings among cancer patients in a palliative care clinic and examined the ability of PMPs, clinical review, and urine drug testing to identify NMOU behaviors. This was a retrospective analysis of consecutive cancer patients seen by palliative care at a safety-net hospital over four years. Demographic, clinical, and psychosocial risk factors for NMOU were extracted from the medical record. Concerning PMP findings were based on prescriber documentation. Logistic regression models identified predictors of documented PMP concerns.
resultsAmong 906 patients, 844 (93%) had PMP reviews at either consultation or a follow-up visit. Of these, 31/844 (4%) demonstrated documented PMP concern. Predictors of documented PMP irregularities included a history of illicit drug use (OR 6.30, 95% CI: 2.35-17.06), opioid use for non-malignant pain (OR 19.49, 95% CI: 6.24-60.90), and a family history of illicit drug use (OR 5.42, 95% CI: 0.96-25.04). DISCUSSION: A total of 166 patients (20%) were identified as having NMOU behaviors based on clinical review; in contrast, PMP review identified only 31 (4%) patients with NMOU behaviors, and two (6%) were missed by clinical review. Documented PMP concern was low in cancer patients. Clinical review identified most patients with NMOU behaviors, with limited contribution from PMP review. Our findings suggest that PMP should not be used in isolation when assessing opioid-related risk in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.